Pfizer signs strategic cooperation pact with China's Sinopharm
April 13 (Reuters) - Pfizer PFE.N said on Thursday it
has signed a strategic cooperation agreement with China's
Sinopharm Group 1099.HK , and plans to seek approval to market
12 innovative drugs in China through 2025.
Sinopharm's president Liu Yong said during the signing event
in Shanghai on Wednesday that the cooperation will involve
accelerating the delivery of Pfizer's new drugs to patients,
according to a statement from Pfizer.
(Reporting by Brenda Goh, Meg Shen and Ethan Wang; Editing by
Bernadette Baum)
((Ethan.Wang@thomsonreuters.com;))
Recent news on Sinopharm
See all newsBrief: Sinopharm Group Says 9M Sinopharm Accord Net Income Attributable RMB952.5 Million (Oct 20)
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For